Jun 12 |
pHOXWELL for COVID-19: real-time meta analysis of 1 study | |
| Significantly lower risk is seen for cases. Meta analysis using the most serious outcome reported shows 47% [29‑62%] lower risk. Currently there is very limited data, with only one study to date. No treatment is 100% effective... | ||
Jul 25 2022 |
et al., Journal of Clinical Virology, doi:10.1016/j.jcv.2022.105248 | Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial. |
| 47% fewer symptomatic cases (p<0.0001) and 63% lower IgG positivity (p<0.0001). 648 patient RCT pHOXWELL nasal spray in India, showing significantly lower IgGS+ and significantly lower symptomatic cases with treatment. pHOXWELL includes a combination of natural virucidal agents and is designed to mimic the fluid surr.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.